Clinical Trials Logo

Filter by:
NCT ID: NCT05277740 Recruiting - Clinical trials for Relapsing Remitting Multiple Sclerosis

Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis

Start date: September 1, 2022
Phase:
Study type: Observational

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by CIS and RRMS and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to identify which metrics-or combination thereof-can serve as reliable biomarker of CIS and RRMS disease progression and cognitive status.

NCT ID: NCT05277051 Recruiting - Neoplasms Clinical Trials

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

NCT ID: NCT05275439 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Start date: March 17, 2022
Phase: Phase 1
Study type: Interventional

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

NCT ID: NCT05273411 Recruiting - Ketosis Clinical Trials

The Effect of Different Ketone Supplements on Blood β-OHB and Blood Glucose in Healthy Individuals

Start date: March 24, 2022
Phase: N/A
Study type: Interventional

Ketone bodies are a fuel source and signaling molecule that are produced by your body during prolonged fasting or if you consistently eat at low-carbohydrate diet. Blood ketones can be used as a source of energy during fasting and are used by your brain as an alternative source of fuel to glucose. Previous studies have found that ketones, when consumed in form of a supplement drink, can increase blood ketone levels and lower blood glucose, the amount of sugar in your blood. This is of potential interest for individuals with high blood sugar, such as people living with type 2 diabetes. However, there are different types of ketone supplements that differ in how they are metabolized in the body. Little is known about how these supplements affect blood ketone and blood glucose levels. The main objective of this study is to determine the effect of three different ketone supplements on blood ketones and blood glucose. The results of this pilot study will be used to guide future research for larger and more extensive studies on ketone supplements.

NCT ID: NCT05273320 Recruiting - Clinical trials for Intellectual Disability

Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

N-AND
Start date: March 17, 2022
Phase: Phase 1
Study type: Interventional

Innovative treatments are urgently needed for severe behavioural problems (SBPs) in adults with intellectual and developmental disabilities (IDD). Although a synthetic cannabinoid, nabilone may be a plausible and safe alternative to treat SBP, safety and efficacy of nabilone in people with IDD has never been evaluated. The investigators propose to conduct this first-ever Phase I pre-pilot open-label clinical trial to collect data on the tolerability and safety profile of nabilone in adults with IDD, and explore changes in SBP pre- and post-treatment. The results will inform a next-stage pilot randomized controlled trial, followed by a fully powered trial eventually.

NCT ID: NCT05272319 Recruiting - Liver Diseases Clinical Trials

Genetic Collection Protocol

Start date: April 6, 2022
Phase:
Study type: Observational

This study involves the one-time collection of whole blood or saliva samples for the extraction and storage of DNA for use in ongoing and future ChiLDReN studies.

NCT ID: NCT05271409 Recruiting - Clinical trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Meteoroid
Start date: August 30, 2022
Phase: Phase 3
Study type: Interventional

The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period

NCT ID: NCT05270759 Recruiting - Acute Kidney Injury Clinical Trials

Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy

TECHNO-HDF
Start date: March 1, 2022
Phase:
Study type: Observational

This prospective cohort study aim to investigate the ability of multiple types of assessments including 1) the modified Venous Excess Ultrasound (VExUS) assessment, 2) non-invasive estimation of absolute blood volume (ABV), and 3) change in carotid Doppler at the start of IKRT to predict IDHE in acutely ill hospitalized patients. The secondary aim will be to determine whether each modality improves the prediction of IHDE compared to the evaluation of the attending physician and whether they also predict cerebral hypoxia during IKRT measured by near-infrared spectroscopy (NIRS). Finally, detailed hemodynamic data including relative blood volume monitoring, tissue oximetry, and other parameters will be collected continuously during IKRT sessions enabling exploratory analyses aimed at identifying hemodynamic phenotypes related to IDHE during IKRT.

NCT ID: NCT05270668 Recruiting - Clinical trials for Interstitial Lung Disease

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

ATHENA-SSc-ILD
Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

NCT ID: NCT05269849 Recruiting - Epistaxis Clinical Trials

Sirolimus for Nosebleeds in HHT

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

This pilot study is to determine the safety and efficacy of oral sirolimus (blood trough level 6-10ng/ml) in patients with HHT that are experiencing moderate or severe epistaxis. The effect of oral sirolimus on epistaxis will be compared to baseline using the Patient-Reported Outcome of cumulative weekly nose Bleeding Duration (PRO-CB). The PRO-CB association with biomarker variability over the duration of the study will be investigated. In the pilot study subjects will be treated with 2mg of sirolimus once daily to obtain a trough level of 6-10ng/ml for 3 months.